icone plus
Contact Abonnez-vous aux actualités
Reason for request
Inclusion
Clinical Benefit
Substantial
Substantial actual benefit
Clinical Added Value
important
KALYDECO offers a substantial improvement in actual benefit (IAB II) in the treatment of cystic fibrosis in patients aged 6 years and older with the G551D-CFTR mutation.
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
AQN0hA26HuawBawU
Listen
